IRIS
VERGARO, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.072
EU - Europa 4.388
AS - Asia 1.382
SA - Sud America 26
Continente sconosciuto - Info sul continente non disponibili 22
AF - Africa 4
OC - Oceania 3
Totale 10.897
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.834
IT - Italia 1.484
GB - Regno Unito 980
SG - Singapore 726
DE - Germania 413
UA - Ucraina 389
RU - Federazione Russa 298
CN - Cina 273
IE - Irlanda 239
CA - Canada 232
VN - Vietnam 208
SE - Svezia 163
DK - Danimarca 117
FR - Francia 92
FI - Finlandia 87
HK - Hong Kong 65
PK - Pakistan 30
IN - India 29
NL - Olanda 26
EU - Europa 21
AT - Austria 20
PL - Polonia 13
BE - Belgio 12
RO - Romania 12
ES - Italia 10
LT - Lituania 9
CH - Svizzera 8
BR - Brasile 7
ID - Indonesia 7
AR - Argentina 6
IR - Iran 6
PH - Filippine 6
AM - Armenia 5
JP - Giappone 5
PE - Perù 5
BD - Bangladesh 4
TH - Thailandia 4
AU - Australia 3
CL - Cile 3
HU - Ungheria 3
KZ - Kazakistan 3
SM - San Marino 3
TW - Taiwan 3
CZ - Repubblica Ceca 2
EC - Ecuador 2
GE - Georgia 2
GH - Ghana 2
MX - Messico 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
TR - Turchia 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CO - Colombia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GR - Grecia 1
IL - Israele 1
IS - Islanda 1
LK - Sri Lanka 1
LV - Lettonia 1
NO - Norvegia 1
RS - Serbia 1
SA - Arabia Saudita 1
SC - Seychelles 1
Totale 10.897
Salva come PNG Salva come JPEG
Città #
Singapore 590
Southend 540
Chandler 443
Fairfield 411
San Mateo 329
Woodbridge 327
Houston 284
Ann Arbor 243
Dublin 233
Cambridge 232
Falls Church 232
Seattle 225
Boardman 186
Wilmington 183
Jacksonville 182
Ottawa 180
Ashburn 178
Dearborn 162
Portsmouth 145
Stevenage 141
Beijing 118
Dong Ket 115
Lawrence 106
Pisa 106
Milan 91
Rome 88
Santa Clara 58
Florence 55
San Diego 47
Helsinki 44
Los Angeles 41
Fremont 39
London 38
Redwood City 36
Brooklyn 32
Hong Kong 27
Montréal 27
Padova 25
Washington 25
Assago 24
Palermo 24
Bologna 23
Munich 22
Central District 20
Livorno 20
Shanghai 18
Frankfurt am Main 17
Genoa 17
Lappeenranta 17
Naples 17
Old Bridge 17
Bari 16
Buti 15
Turin 15
Lucca 14
Toronto 14
Hounslow 13
Norwalk 13
Brussels 12
Dallas 12
Islamabad 12
Redmond 12
Warsaw 12
Shenzhen 11
Napoli 10
New Delhi 10
Verona 10
Vienna 10
Amsterdam 9
Brescia 9
Cascina 9
Catania 9
Nanjing 9
Wandsworth 9
Kilburn 8
Parma 8
West Jordan 8
Zirl 8
Augusta 7
Bucharest 7
Forlì 7
Jinan 7
Nuremberg 7
Pavia 7
Perugia 7
Berlin 6
Chiswick 6
Grammichele 6
Pescia 6
Siena 6
Taranto 6
Treviso 6
Veglie 6
Venice 6
Acton 5
Chicago 5
Foggia 5
Hanover 5
Hyderabad 5
Lahore 5
Totale 7.230
Salva come PNG Salva come JPEG
Nome #
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 577
Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging 220
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 171
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis 167
Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly? 164
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 162
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 157
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure 157
Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches 153
Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy 151
Update sui biomarcatori nello scompenso cardiaco. 151
Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice 148
Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators 148
CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy 146
Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism 144
Prognostic value of plasma Renin activity in heart failure. 135
Cardiac light-chain deposition disease relapsing in the transplanted heart 132
Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy 130
The search for efficient diagnostic and prognostic biomarkers of heart failure 129
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 129
Correction of procedural arterial pseudoaneurysms: Established and novel procedures 128
Modern diagnostic and therapeutical approach to cardiac AL amyloidosis and neuroendocrine model of heart failure: lessons from a clinical case. 125
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible? 125
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis 121
Sex-related differences in chronic heart failure 114
A simple echocardiographic score to rule out cardiac amyloidosis 112
Adrenergic activation in heart failure: blockade or rebalance? 108
How to take arms against central apneas in heart failure 105
Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure 105
Upright Cheyne-Stokes Respiration in Patients With Heart Failure 100
Heart, kidney and FGF23: Les liaisons dangereuses 99
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 97
Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry 96
NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure 94
Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure 92
High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure 92
[18F]-Florbetaben PET/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions 92
Cheyne-Stokes respiration and heart failure: pathophysiologicaland clinical implications 90
Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction 88
Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure 84
Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction 83
Management of complications of cardiac amyloidosis: 10 questions and answers 82
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 79
N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure 77
sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T 76
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 76
Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias 76
Classification of patients with cardiac amyloidosis using machine learning models on Italian electronic clinical health records 76
Central And Obstructive Apneas in Heart Failure With Reduced, Mid-Range And Preserved Ejection Fraction. 75
Left ventricular ejection fraction for risk stratification in chronic systolic heart failure 74
Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC) 73
Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction 72
Therapies for cardiac light chain amyloidosis: An update 70
The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target? 70
Contribution of the lung to the genesis of cheyne-stokes respiration in heart failure: Plant gain beyond chemoreflex gain and circulation time 70
Renin profiling predicts neurohormonal response to sacubitril/valsartan 70
Wet is bad: Residual congestion predicts worse prognosis in acute heart failure 69
Quality of life and outcome in heart failure with preserved ejection fraction: When sex matters 68
Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome 68
Sex-related differences in chronic heart failure 67
Mineralocorticoid receptor antagonists for heart failure: a real-life observational study 67
Biomarkers for the diagnosis and management of heart failure 67
Central apnoeas and ticagrelor-related dyspnoea in patients with acute coronary syndrome 65
Cardiogenic shock and acute kidney injury: the rule rather than the exception 64
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 62
In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation 62
Treatment of cardiac transthyretin amyloidosis: an update 61
Atrial amyloidosis: mechanisms and clinical manifestations 60
No Aldosterone Breakthrough With the Neprilysin Inhibitor Sacubitril 59
Sacubitril–valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction 58
Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week 58
Molecular autopsy of sudden cardiac death in the genomics era 58
Heart & kidney failure: Who's afraid of renin angiotensin system blockade? 57
Longer sleep duration and poor sleep quality as risk factors for hyperlipidaemia 57
Use of biomarkers to diagnose and manage cardiac amyloidosis 57
Role of Imaging in Cardiomyopathies 56
Epidemiological and clinical boundaries of heart failure with preserved ejection fraction 56
Biomarkers for the diagnosis and management of heart failure: New frontiers 56
A simple echocardiographic score to rule out cardiac amyloidosis 54
Left ventricular ejection fraction and coronary artery disease in the era of precision medicine 54
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 54
Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance 53
Biomarkers of heart failure with preserved and reduced ejection fraction 52
Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction 52
Subclinical cardiac damage in cancer patients before chemotherapy 52
Current and emerging drug targets in heart failure treatment 52
α-1 Antitrypsin as a potential biomarker in chronic heart failure 51
Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation 50
Deep-learning-based cardiac amyloidosis classification from early acquired pet images 47
Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis 47
Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis 46
Natriuretic peptides. D'où venons-nous? Que sommes-nous? Où allons-nous? 45
Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images 44
Understanding Family History of Heart Disease. A (Good) Patient Interview vs. Genetics 43
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies 43
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 43
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 41
Screening the health status of people working in a university 41
Central Apneas Are More Detrimental in Female Than in Male Patients With Heart Failure 41
Norepinephrine, plasma renin activity and cardiovascular mortality in systolic heart failure 40
Totale 9.134
Salva come PNG Salva come JPEG
Categoria #
all - tutte 96.361
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 96.361
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020647 0 0 0 0 0 135 139 62 119 29 43 120
2020/20212.294 170 193 94 205 120 286 198 136 187 151 243 311
2021/20221.911 161 295 80 196 74 67 201 333 141 195 36 132
2022/20231.334 109 110 62 140 164 175 36 120 251 30 82 55
2023/20241.331 76 36 239 101 73 120 102 65 51 75 55 338
2024/20251.810 112 132 487 200 420 459 0 0 0 0 0 0
Totale 11.129